Health

Health policy conference: fostering investment and innovation in EU healthcare

On 20 May in Brussels, from 2.00 to 6.30 PM, leading voices from EU institutions, the pharmaceutical industry, and public health organisations will come together to explore how to strengthen Europe's healthcare systems through investment and innovation. The event will open with a keynote by Sandra Gallina, Director-General for Health and Food Safety, focusing on building a resilient European Health Union and the role of the Critical Medicines Act. Panels throughout the day will address key priorities, including pharmaceutical legislation reform, fair access to medicines, the potential of AI in healthcare, and securing the supply of critical medicines. Speakers include high-level representatives from the European Commission, European Parliament, EMA, Zentiva, EFPIA, and EUPHA. The final panel will look at how to enhance Europe’s global competitiveness in pharma and biotech, with an emphasis on research, pricing, and innovation-friendly regulation. This event offers a vital platform to align policy, public health needs, and industry strategies for a stronger, more sustainable healthcare future across the EU. REGISTER HERE to join the conversation.

Challenge: Development of a rapid point-of-care antimicrobial susceptibility testing diagnostic medical device by HaDEA

Development of a rapid point-of-care antimicrobial susceptibility testing diagnostic medical device Health and Digital Executive Agency (HaDEA) About  The Health and Digital Executive Agency (HaDEA) has issued a tender within the context of the EU4Health Annual Work Programme 2024.  EU4Health is the fourth and largest of the EU health programmes, providing funding to national authorities, health organisations and other bodies through grants and public procurement, contributing to a healthier Europe HaDEA manages the vast majority of the total EU4Health budget and implements the programme by managing calls for proposals and tenders from 2021 to 2027.   The Challenge   This challenge aims to accelerate the development of innovative point-of-care diagnostic devices capable of delivering antimicrobial susceptibility testing (AST) results within one hour or less from sample collection. The envisioned solutions should also ideally enable simultaneous pathogen identification, with a focus on at least one of the bacteria included in the 2024 WHO bacterial pathogen priority list and/or the fungi Candida spp. and Aspergillus fumigatus. This call also supports the advancement of promising rapid AST technologies currently under development, with the overarching goal of enhancing timely clinical decision-making and addressing the growing threat of antimicrobial resistance.   Timeframe Deadline to apply for Step 1 of the procedure: 12 May 2025, 16:00 CEST. Invitations to submit an offer for Step 2 will be indicatively sent out at the beginning of June, with a deadline for step 2 indicatively in early September.  Who can apply  

• Applicants with solutions of TRL 3-8, with a clear pathway for CE marking in the EU19. By the end of the contract, the product developed should aim at reaching system complete and qualified (TRL 8).

  How to apply  Interested parties are invited to apply on the Funding and Tenders Portal.  Find here all the details of the procedure. The SPIN4EIC consortium is not responsible for the challenges launched by private or public buyers. Each participating entity is solely responsible for its own challenge, including the selection process, communication with applicants, and all information provided to participants.